Lack of tolerance and morphine-induced cross-tolerance to the analgesia of chimeric peptide of Met-enkephalin and FMRFa

Peptides

Volumn 29, Issue 12, 2008, Pages 2266-2275

  Gupta, Kshitij ^a   Vats, Ishwar Dutt ^a   Gupta, Yogendra Kumar ^b   Saleem, Kishwar ^c   Pasha, Santosh ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

Analgesia; Chimeric peptide (YFa); Cross tolerance; Dynorphin A(1 13); Tolerance

Indexed keywords

DYNORPHIN[1-13]; METENKEPHALIN; MORPHINE; PHENYLALANYLMETHIONYLARGINYLPHENYLALANINAMIDE; TYROSYLGLYCYLGLYCYLPHENYLALANYLMETHIONYLLYSYLLYSYLLYSLPHENYLALANYLMETHIONYLARGINYLPHENYLALANINAMIDE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CROSS TOLERANCE; DRUG EFFECT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANALGESIA; ANALGESICS; ANIMALS; DRUG TOLERANCE; DYNORPHINS; ENKEPHALIN, METHIONINE; MALE; MICE; MORPHINE; OLIGOPEPTIDES; PAIN MEASUREMENT; PEPTIDE FRAGMENTS; RECEPTORS, OPIOID, KAPPA; RECOMBINANT FUSION PROTEINS;

EID: 55949101324     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2008.09.013     Document Type: Article

References (43)

1. Aceto M.D., Dewey W.L., Chana J.K., and Lee N.M. Dynorphin A1-13 effects in nontolerant and morphine-dependent rhesus monkeys. Eur J Pharmacol 83 (1982) 139-142
2. Allard M., Geoffre S., Legendre P., Vincent J.D., and Simonnet G. Characterisation of rat spinal cord receptors to FLFQPQRFamide, a mammalian morphine modulating peptide: a binding study. Brain Res 500 (1989) 169-176
3. Bhargava H.N., and Gulati A. Down-regulation of brain and spinal cord m-opioid receptors in morphine tolerant-dependent rats. Eur J Pharmacol 190 (1990) 305-311
4. Chavkin C., and Goldstein A. Dynorphin is a specific endogenous ligand of the κ-opioid receptor. Science (Wash., DC) 215 (1982) 413-415
5. Chen Y., Mestek A., Liu J., and Yu L. Molecular cloning of a rat κ-opioid receptor reveals sequence similarities to the μ- and δ-opioid receptors. Biochem J 295 (1993) 625-628
6. D'Amour F.E., and Smith D.L. A method for determining loss of pain sensation. J Pharmacol Exp Ther 72 (1941) 74-79
7. Ferguson S.S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53 (2001) 1-24
8. Galina H.Z., and Kastin A.J. Existence of antiopiate system as illustrated by MIF-1/Tyr-MIF-1. Life Sci 39 (1986) 2153-2159
9. Garzon J., Sanchez-Blazquez P., Gerhart J., Loh H.H., and Lee N.M. Dynorphin1-13: interaction with other opiate ligand bindings in vitro. Brain Res 302 (1984) 392-396
10. Gether U., and Kobilka B.K. G protein-coupled receptors. II. Mechanism of agonist activation. J Biol Chem 273 (1998) 17979-17982
11. Goodman C.B., Elmer G.I., Yang H.-Y.T., Lee C.H., and Rothman R.B. Modulation of opioid receptors by anti-opioid peptides. In: Tseng L.F. (Ed). The pharmacology of opioid peptides (1995), Harwood Academic Publishers, GmbH, Singapore 303-319
12. Gouarderes C., Sutak M., Zajac J.-M., and Jhamandas K. Antinociceptive effects of intrathecally administered F8Famide and FMRFamide in the rat. Eur J Pharmacol 237 (1993) 73-81
13. Grecksch G., Bartzsch K., Widera A., Becker A., Höllt V., and Koch T. Development of tolerance and sensitization to different opioid agonists in rats. Psychopharmacology 186 (2006) 177-184
14. Greenberg M.J., Painter S.D., Dobble K.E., Naggle G.T., Price D.A., and Lehman H.K. The molluscan neurosecretory peptide FMRFamide: comparative pharmacology and relationship to the enkephalins. Fed Proc 42 (1983) 82-86
15. Gupta S., Pasha S., Gupta Y.K., and Bhardwaj D.K. Chimeric peptide of met-enkephalin and FMRFa induces antinociception and attenuates development of tolerance to morphine antinociception. Peptides 20 (1999) 471-478
16. Hanif K., Gupta K., Gupta S., Gupta Y.K., Maiti S., and Pasha S. Chimeric peptide of met-enkephalin and FMRFa: effect of chlorination on conformation and antinociception. Neuro Lett 403 (2006) 131-135
17. Harrison L.M., Kastin A.J., and Zadina J.E. Opiate tolerance and dependence: receptors, G-proteins and antiopiates. Peptides 19 (1998) 1603-1630
18. Hooke L.P., He L., and Lee N.M. Dynorphin A modulates acute and chronic opioid effects. J Pharmacol Exp Ther 273 (1995) 292-297
19. Inturrisi C.E., Umans J.G., Wolff D., Stern A.S., Lewis R.V., Stein S., et al. Analgesic activity of the naturally occurring heptapeptide met5enkephalin-Arg6-Phe7. Proc Natl Acad Sci USA 81 (1980) 5512-5514
20. Jordan A.B., Cvejic S., and Devi L.A. Kappa opioid receptor endocytosis by Dynorphin peptides. DNA Cell Biol 19 1 (2000) 19-27
21. Koch T., and Volker H. Role of receptor internalization in opioid tolerance and dependence. Pharmacol Ther 117 (2008) 199-206
22. Koenig J.A., and Edwardson J.M. Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol Sci 18 (1997) 276-287
23. Law P.Y., Erickson L.J., El-Kouhen R., Dicker L., Solberg J., Wang W., et al. Receptor density and recycling affect the rate of agonist-induced desensitization of μ-opioid receptor. Mol Pharmacol 58 (2000) 388-398
24. Law P.Y., Hom D.S., and Loh H.H. Opiate receptor downregulation and desensitization in neuroblastoma 3 glioma NG108-15 hybrid cells are two separate cellular adaptation processes. Mol Pharmacol 24 (1983) 413-424
25. Liu-Chen L.-Y. Agonist-induced regulation and trafficking of κ opioid receptors. Life Sci 75 (2004) 511-536
26. Majane E.A., Iadarola M.J., and Yang H.-Y.T. Distribution of Met5-enkephalin-Arg6-Phe7 in rat spinal cord. Brain Res 264 (1983) 336-369
27. Malin D.H., Lake J.R., Hammond M.V., Fowler D.E., Rogillio R.B., Brown S.L., et al. FMRF-NH2 like mammalian octapeptide: possible role in opiate dependence and abstinence. Peptides 11 (1990) 969-972
28. Panula P., Kalso E., Nieminen M.-L., Kontinen V., Brandt A., and Pertovaara A. Neuropeptide FF and modulation of pain. Brain Res 848 (1999) 191-196
29. Gutstein HB, Akil H. In: Hardman JG, Limbird LE, Gilmann AG, editors. Goodman & Gilmann's The Pharmacological Basis of Therapeutics. USA: McGraw-Hill; 2001 [Chapter 23] p. 575.
30. Rossier J., Audigier Y., Ling N., Cros J., and Udenfriend S. Metenkephalin- Arg6-Phe7, present in high amounts in brain of rat, cattle and man, is an opioid agonist. Nature 288 (1980) 88-90
31. Salamon Z., Cowell S., Varga E., Yamamura H.I., Hruby V.J., and Tollin G. Plasmon resonance studies of agonist/antagonist binding to the human δ-opioid receptor: new structural insights into receptor-ligand interactions. Biophys J 79 (2000) 2463-2474
32. Salamon Z., Hruby V.J., Tollin G., and Cowell S. Binding of agonists, antagonists and inverse agonists to the human δ-opioid receptor produces distinctly different conformational states distinguishable by Plasmon waveguide resonance spectroscopy. J Pept Res 60 (2002) 322-328
33. Schwyzer R. Molecular mechanism of opioid receptor selection. Biochemistry 25 (1986) 6335-6342
34. Schwyzer R. Peptide-membrane interactions and a new principle in quantitative structure-activity relationships. Biopolymers 31 (1991) 785-792
35. Schwyzer R. 100 years lock and key concept: are peptides key shaped and guided to their receptors by the target cell membrane?. Biopolymers (Pept Sci) 37 (1995) 5-16
36. Takemori A.E., Loh H.H., and Lee N.M. Suppression by dynorphin A and [des-tyr] dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice. J Pharmacol Exp Ther 266 (1993) 121-124
37. Tang J., Yang H.-Y.T., and Costa E. Inhibition of spontaneous and opiate-modified nociception by an endogenous neuropeptide with Phe-Met-Arg-Phe-NH2-like immunoreactivity. Proc Natl Acad Sci USA 81 (1984) 5002-5005
38. Tanowitz M., and von Zastrow M. A novel endocytic recycling signal that distinguishes the membrane trafficking of naturally occurring opioid receptors. J Biol Chem 278 (2003) 45978-45986
39. Vats I.D., Dolt K.S., Kumar K., Karar J., Nath M., and Pasha S. YFa, a chimeric opioid peptide, induces kappa-specific antinociception with no tolerance development during 6 days of chronic treatment. J Neurosci Res 86 7 (2008) 1599-1607
40. Wen H.L., and Ho W.K. Suppression of withdrawal symptoms by dynorphin in heroin addicts. Eur J Pharmacol 82 (1982) 183-186
41. Werling L., Mc Mohan P.N., and Cox B.M. Selective changes in m opioid receptor properties induced by chronic morphine exposure. Proc Natl Acad Sci USA 86 (1989) 6393-6397
42. Young E.A., Walker J.M., Lewis M.E., Houghten R.A., Woods J.H., and Akil H. [3H] dynorphin A binding and kappa selectivity of prodynorphin peptides in rat, guinea-pig and monkey brain. Eur J Pharmacol 121 (1986) 355-365
43. Zhang S., Tong Y., Tian M., Dehaven R., Cortesburgos L., Mansson E., et al. Dynorphin A as a potential endogenous ligand for four members of the opioid receptor gene family. J Pharmacol Exp Ther 286 (1998) 136-141